ARAY Stock - Accuray Incorporated
Unlock GoAI Insights for ARAY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $458.50M | $446.55M | $447.61M | $429.91M | $396.29M |
| Gross Profit | $146.97M | $142.92M | $153.96M | $159.96M | $159.51M |
| Gross Margin | 32.1% | 32.0% | 34.4% | 37.2% | 40.3% |
| Operating Income | $7.84M | $504,000 | $2.38M | $8.15M | $22.23M |
| Net Income | $-1,591,000 | $-15,545,000 | $-9,280,000 | $-5,347,000 | $-6,311,000 |
| Net Margin | -0.3% | -3.5% | -2.1% | -1.2% | -1.6% |
| EPS | $-0.02 | $-0.16 | $-0.10 | $-0.06 | $-0.07 |
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 13th 2024 | ROTH MKM | Initiation | Buy | $9 |
| June 23rd 2022 | B. Riley Securities | Initiation | Buy | $7.5 |
Earnings History & Surprises
ARAYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.01 | $-0.18 | -1700.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $0.03 | $0.01 | -65.6% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $-0.05 | $-0.01 | +80.0% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $-0.01 | $0.02 | +300.0% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.03 | $-0.04 | -24.5% | ✗ MISS |
Q3 2024 | Sep 19, 2024 | — | $0.03 | — | — |
Q2 2024 | May 1, 2024 | $-0.01 | $-0.06 | -380.0% | ✗ MISS |
Q1 2024 | Jan 31, 2024 | $-0.07 | $-0.10 | -42.9% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.02 | $-0.03 | -40.0% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.01 | $-0.03 | -400.0% | ✗ MISS |
Q2 2023 | Apr 26, 2023 | $0.00 | $0.01 | +185.7% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $-0.02 | $-0.02 | -25.0% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-0.02 | $-0.06 | -172.7% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $-0.06 | $-0.01 | +83.3% | ✓ BEAT |
Q1 2022 | Jan 26, 2022 | — | $0.00 | — | — |
Q4 2021 | Nov 3, 2021 | $-0.01 | $-0.01 | -75.1% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.01 | $-0.01 | -54.6% | ✗ MISS |
Latest News
Accuray Announces First Phase Of Its Comprehensive Strategic, Operational, And Organizational Transformation Plan; Workforce Optimization Actions Will Affect ~ 15% Of Company's Employees; Expects To Incur Restructuring Charges In Its Fiscal Second, Third And Fourth Quarters Totaling ~ $11M; Continues To Maintain Its Forecasts For Full Year Fiscal 2026
➖ NeutralAccuray shares are trading lower after the company reported a Q1 EPS miss. Also, BTIG lowered the price target on the stock from $5 to $4.
📉 NegativeBTIG Maintains Buy on Accuray, Lowers Price Target to $4
➖ NeutralAccuray Affirms FY2026 Sales Guidance of $471.000M-$485.000M vs $475.150M Est
➖ NeutralAccuray Q1 EPS $(0.16) Misses $(0.06) Estimate, Sales $93.942M Beat $91.350M Estimate
➖ NeutralAccuray Reports Preliminary Q1 FY26 Revenue Of $92.5M-$94M; Product Sales Lag In EIMEA And China, EBITDA At ~($4M)
📉 NegativeAccuray Appoints Steve La Neve As CEO, Effective Immediately, Succeeding Suzanne Winter
➖ NeutralAccuray Announces First Patients Treated Through 5D Clinics In Melbourne Using CyberKnife S7 System
📈 PositiveAccuray And UW SMPH Sign MOU To Advance Online Adaptive Radiotherapy On Accuray Helical Radiation Treatment Delivery Platform
📈 PositiveAccuray Inc. Advances Adaptive Radiotherapy With Introduction Of Accuray Stellar Solution
📈 PositiveAccuray shares are trading higher. Last week, the company reported better-than-expected Q4 sales results.
📈 PositiveAccuray Q4 Revenue Hits $128 Million
📈 PositiveAccuray restructures debt, secures new $190M financing; shares down
📉 NegativeFrequently Asked Questions about ARAY
What is ARAY's current stock price?
What is the analyst price target for ARAY?
What sector is Accuray Incorporated in?
What is ARAY's market cap?
Does ARAY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ARAY for comparison